企業プロフィール
ALX Oncology 株価・ニュース・カタリスト
- ティッカー:
- ALXO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.97 USD (+0.51%)
終値
最終更新: 2026年8月17日
240M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ALXO closed up 0.51% at $1.97. No new same-company headline was identified in the current news window.
企業概要
CD47-Directed Immuno-Oncology
ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells.
Evorpacept
Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other anticancer medicines. Current development emphasizes HER2-positive cancers and biomarker-selected patients with high CD47 expression.
ALX2004
ALX2004 is a next-generation clinical candidate that expands the company's innate-immunity pipeline beyond evorpacept and is undergoing initial safety evaluation.
今後のカタリスト
- Initial safety data from the Phase 1 study of ALX2004 in the second half of 2026.
- Topline data from the Phase 2 ASPEN-09-Breast study of evorpacept in mid-2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。